Patient Derived Xenograft (PDX) Models Market - 2026-2033

May 2026 | 64 pages | ID: P0E7E8569567EN
DataM Intelligence

Abstracts

Patient Derived Xenograft (PDX) Models Marketis is growing with a CAGR of 12.70% during the forecast period 2026-2035.

The Patient Derived Xenograft (PDX) Models Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Patient Derived Xenograft (PDX) Models Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Type

• Mice Model*
• Rats Model

By Tumor Type

• Gastrointestinal Tumor Model*
• Gynecological Tumor Model
• Respiratory Tumor Model
• Other Tumor Model

By End User

• Preclinical Drug Development*
• Biomarker Analysis
• Basic Cancer Research
• Pharmaceutical & Biotechnology Companies *
• Contract Research Organizations (CROs)
• Academic & Research Institutions
• Others

Regional Analysis for Patient Derived Xenograft (PDX) Models Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Patient Derived Xenograft (PDX) Models Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Market Snippet by Type
3.2. Market Snippet by Tumor Type
3.3. Market Snippet by Application
3.4. Market Snippet by End User
3.5. Market Snippet by Region

4. MARKET DYNAMICS

4.1. Market Impacting Factors
  4.1.1. Drivers
    4.1.1.1. The growing demand for personalized medicine will drive the market growth
    4.1.1.2. Rising demand for humanized PDX models is driving the market growth
  4.1.2. Restraints:
    4.1.2.1. High cost of personalized PDX models will hamper the market growth in the forecast period
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Unmet Needs

6. COVID-19 ANALYSIS

6.1. Analysis of Covid-19 on the Market
  6.1.1. Before COVID-19 Market Scenario
  6.1.2. Present COVID-19 Market Scenario
  6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. BY TYPE

7.1. Introduction
  7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  7.1.2. Market Attractiveness Index, By Type Segment
7.2. Mice Model*
  7.2.1. Introduction
  7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. Rats Model

8. BY TUMOR TYPE

8.1. Introduction
  8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type
  8.1.2. Market Attractiveness Index, By Tumor Type
8.2. Gastrointestinal Tumor Model*
  8.2.1. Introduction
  8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3. Gynecological Tumor Model
8.4. Respiratory Tumor Model
8.5. Other Tumor Model

9. BY APPLICATION

9.1. Introduction
  9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  9.1.2. Market Attractiveness Index, By Application
9.2. Preclinical Drug Development*
  9.2.1. Introduction
  9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. Biomarker Analysis
9.4. Basic Cancer Research

10. BY END USER

10.1. Introduction
  10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
  10.1.2. Market Attractiveness Index, By End User Segment
10.2. Pharmaceutical & Biotechnology Companies *
  10.2.1. Introduction
  10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
10.3. Contract Research Organizations (CROs)
10.4. Academic & Research Institutions
10.5. Others

11. BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type
  11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.2.7.1. U.S.
    11.2.7.2. Canada
    11.2.7.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type
  11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.3.7.1. Germany
    11.3.7.2. U.K.
    11.3.7.3. France
    11.3.7.4. Italy
    11.3.7.5. Spain
    11.3.7.6. Rest of Europe
11.4. South America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type
  11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.4.7.1. Brazil
    11.4.7.2. Argentina
    11.4.7.3. Rest of South America
11.5. Asia Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type
  11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.5.7.1. China
    11.5.7.2. India
    11.5.7.3. Japan
    11.5.7.4. Australia
    11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type
  11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. COMPETITIVE LANDSCAPE

12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. Key Companies to Watch
12.5. Company with disruptive technology
12.6. Start Up Companies

13. GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODELS MARKET- COMPANY PROFILES

13.1. Charles River Laboratories*
  13.1.1. Company Overview
  13.1.2. Product Portfolio and Description
  13.1.3. Key Highlights
  13.1.4. Financial Overview
13.2. Envigo
13.3. JSR Corporation (Crown Bioscience Inc.)
13.4. Champions Oncology, Inc.
13.5. EPO Berlin-Buch GmbH
13.6. Hera BioLabs
13.7. Horizon Discovery Group plc
13.8. WuXi AppTec
13.9. BEIJING IDMO Co. Ltd.
13.10. Shanghai ChemPartner Co., Ltd..(*LIST NOT EXHAUSTIVE)

14. DATAM INTELLIGENCE

14.1. Appendix
14.2. About Us and Services
14.3. Contact Us